Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом * - Журнал Системные Гипертензии №1 (2006)
Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом *
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Bertel O, Marx B, Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med 1987; 82–29.
2. Meyer JS, Rogers RL, Mortel RF. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16 (6): 985–90.
3. Hares P, James IM, Griffith D. Effect of acebutolol on cerebral circulation of a man. Br J Clin Pharmacol 1977; 4: 373–5.
4. Fuijshima M, Ibayashi S, Fugii K et al Effects of long-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17–5.
5. Fogari R, Zoppi A, Corradi L et al. b-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 534–9.
6. Vulpis V, Antonacci A, Prandi P et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189–93.
7. Верещагин Н.В.,Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–9.
9. Frithz G. Influense on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229–30.
10. Fogari R et al. b-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (suppl 5): S76.
11. Chang PC, van Veen S, Vermeij P, van Brummelen P. Double-blind compason of the b1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S58–60.
12. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61–4.
13. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
14. Haneda T, Ido A, Fijikane T et al. Effect of bisoprolol, a b1-selective b-blocer, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jpn J Geriat 1998; 35: 33–8.
15. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influece of bisiprolol on blood glucose, glucosuria and haemoglobin A1, in non-insulin-dependent diabetics. J Cardivasc Pharmacol 1986; 8 (suppl 11): s 96–9.
16. Dominguez LJ, Barbagallo M, Jacober SJ et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997; 10: 1349–55.
2. Meyer JS, Rogers RL, Mortel RF. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16 (6): 985–90.
3. Hares P, James IM, Griffith D. Effect of acebutolol on cerebral circulation of a man. Br J Clin Pharmacol 1977; 4: 373–5.
4. Fuijshima M, Ibayashi S, Fugii K et al Effects of long-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17–5.
5. Fogari R, Zoppi A, Corradi L et al. b-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 534–9.
6. Vulpis V, Antonacci A, Prandi P et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189–93.
7. Верещагин Н.В.,Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–9.
9. Frithz G. Influense on plasma-insulin and blood-glucose by treatment with bisoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229–30.
10. Fogari R et al. b-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (suppl 5): S76.
11. Chang PC, van Veen S, Vermeij P, van Brummelen P. Double-blind compason of the b1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S58–60.
12. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61–4.
13. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
14. Haneda T, Ido A, Fijikane T et al. Effect of bisoprolol, a b1-selective b-blocer, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Jpn J Geriat 1998; 35: 33–8.
15. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influece of bisiprolol on blood glucose, glucosuria and haemoglobin A1, in non-insulin-dependent diabetics. J Cardivasc Pharmacol 1986; 8 (suppl 11): s 96–9.
16. Dominguez LJ, Barbagallo M, Jacober SJ et al. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens 1997; 10: 1349–55.
Авторы
В.Б.Мычка, В.Б.Сергиенко, В.В.Горностаев, И.М.Двоскина, И.Е.Чазова
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.